Are megamergers bad for business? Is it time for biotech’s biggest gathering to find a new home? And can a “need” be anything but “unmet”?

We discuss all that and more on 2019’s first episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Matthew Herper joins us to break down Bristol-Myers Squibb’s plot to acquire Celgene for $74 billion and its implications for the industry at large. Then we talk about what to expect at next week’s J.P. Morgan Healthcare Conference and dig into whether biotech’s biggest meeting has outgrown its environs. Finally, veteran CEO whisperer and W20 Group Global Practice Leader Mike Huckman stops by to count down the 10 most egregious bits of corporate jargon spouted by biotech executives.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy